23andMe Completion, Competitors and their Products Assignment

23andMe Completion, Competitors and their Products - Assignment Example The main competitors for the company include deCODEme genetics, Navigenics and pathways genomics. The deCODEme genetics is situated in Iceland and is used to identify various human genes that are associated with a variety of human genes that have been associated with various common diseases. It is known to have isolated a variety of genes known to be involved with schizophrenia, cardiovascular disease and even cancer. Pathway Genomics is located in San Diego and is also privately held and it deals with personal genomics. It uses advanced technologies of genetic testing to come up with a personalized report regarding the career status of an individual, the response of medication, ancestral history and the probability of the development of a variety of complex diseases. The company then provides this report to the patient in the presence of a physician. Navigenics is also privately held and it also deals with personal genomics and is located in the Foster City in California. It makes u se of genetic testing to assist people in the identification of their individual risks for various health conditions facing them. 23andMe offers their saliva genome testing kit for only $99. The only thing that a client has to do is to spit into a tube and mail it to the company. The company then comes up with results for the client in question and uploads it online for the client to download using their personal details. This makes the company quite effective and time-saving as opposed to the competitors. For instance, deCODEme had announced the availability of online services by individuals sending a cheek swab for their details about the risk of diseases and their ancestry for $985. They had launched this service in 2007 and it had a relative advantage of offering a comprehensive genome scan and analysis online. However,  this online service was discontinued in 2007 giving 23andMe the relative advantage of continuing its online genome testing service in a more cost-effective manner.